Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h)
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The present clinical trial will be conducted in order to compare the bioavailability of
rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 13.3
mg/24 h (Luye Pharma AG, Germany) and the marketed Reference product Exelon® 13.3 mg/24 h
transdermales Pflaster (Novartis Pharma GmbH, Germany) after multiple patch applications.
Each of both treatments will last for 11 days with a washout period of 14 days between the
treatments.